Extended hold on Arikace dogs Insmed and delays verdict on liposomes in CF
This article was originally published in Scrip
Executive Summary
The FDA is continuing its clinical hold on Arikace, the clinical hold placed in August on Phase III trials of Arikace, a hotly-tipped cystic fibrosis candidate, until second species carcinogenicity data is generated. This will significantly delay the development of this keenly awaited antibiotic which is spearheading new liposomal technology.